Contineum Therapeutics Financials
Financial Health Signals
Contineum Therapeutics passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Contineum Therapeutics generates $0.78 in operating cash flow (-$32.8M OCF vs -$42.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Contineum Therapeutics (CTNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Contineum Therapeutics generated $0 in revenue in fiscal year 2024. This represents a decrease of 100.0% from the prior year.
Contineum Therapeutics's EBITDA was -$50.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 411.2% from the prior year.
Contineum Therapeutics generated -$33.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 276.2% from the prior year.
Contineum Therapeutics reported -$42.3M in net income in fiscal year 2024. This represents a decrease of 286.0% from the prior year.
Contineum Therapeutics earned $-2.18 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 2825.0% from the prior year.
Contineum Therapeutics held $21.9M in cash against $0 in long-term debt as of fiscal year 2024.
Contineum Therapeutics invested $38.4M in research and development in fiscal year 2024. This represents an increase of 39.2% from the prior year.
Contineum Therapeutics spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
Contineum Therapeutics invested $514K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 24.2% from the prior year.
CTNM Income Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | N/A | $0-100.0% | $50.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $11.0M+13.0% | $9.7M+23.1% | $7.9M | N/A | $6.5M-31.3% | $9.5M |
| SG&A Expenses | $3.9M+21.4% | $3.2M+6.7% | $3.0M | N/A | $1.6M-2.1% | $1.6M |
| Operating Income | -$14.9M-15.1% | -$13.0M-18.5% | -$10.9M | N/A | -$8.1M-120.7% | $38.9M |
| Interest Expense | N/A | $0 | $0 | N/A | $0-100.0% | $116K |
| Income Tax | N/A | $0 | $0 | N/A | -$118K-116.2% | $729K |
| Net Income | -$12.8M-24.6% | -$10.3M-14.0% | -$9.0M | N/A | -$6.3M-115.0% | $41.6M |
| EPS (Diluted) | N/A | $-0.40 | $-0.39 | N/A | $-2.69-420.2% | $0.84 |
CTNM Balance Sheet
| Metric | Q3'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|
| Total Assets | $190.8M-10.3% | $212.8M-3.8% | $221.4M+69.8% | $130.4M | N/A | N/A |
| Current Assets | $184.9M-10.4% | $206.4M-6.3% | $220.3M+72.5% | $127.7M | N/A | N/A |
| Cash & Equivalents | $42.6M+94.3% | $21.9M-71.6% | $77.2M+397.4% | $15.5M | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.4M-29.8% | $14.8M+283.7% | $3.9M-98.1% | $198.3M | N/A | N/A |
| Current Liabilities | $6.4M-36.2% | $10.0M+166.8% | $3.7M-31.8% | $5.5M | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $180.5M-8.9% | $198.1M-8.9% | $217.5M+420.2% | -$67.9M-11.1% | -$61.1M-10.3% | -$55.4M |
| Retained Earnings | -$162.2M-38.2% | -$117.4M-26.8% | -$92.6M-23.2% | -$75.1M | N/A | N/A |
CTNM Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.2M-19.6% | -$10.2M-20.0% | -$8.5M+20.6% | -$10.7M-99.1% | -$5.4M-113.2% | $40.7M |
| Capital Expenditures | $98K-41.0% | $166K+39.5% | $119K-61.5% | $309K+1304.5% | $22K-29.0% | $31K |
| Free Cash Flow | -$12.3M-18.6% | -$10.4M-20.3% | -$8.6M+21.7% | -$11.0M-104.0% | -$5.4M-113.3% | $40.6M |
| Investing Cash Flow | $14.9M+259.1% | -$9.4M+75.9% | -$38.9M-530.8% | $9.0M+122.9% | -$39.5M+11.2% | -$44.5M |
| Financing Cash Flow | $19.1M+2875.9% | $642K-99.4% | $108.4M+33858.3% | -$321K-103.1% | $10.3M-77.9% | $46.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
CTNM Financial Ratios
| Metric | Q3'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | 77.9% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 83.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -6.7%-2.0pp | -4.8%-0.7pp | -4.1% | N/A | N/A | N/A |
| Current Ratio | 29.07+8.4 | 20.69-38.2 | 58.92+35.6 | 23.29 | N/A | N/A |
| Debt-to-Equity | 0.06-0.0 | 0.07+0.1 | 0.02+2.9 | -2.92 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | 81.3% |
Similar Companies
Frequently Asked Questions
What is Contineum Therapeutics's annual revenue?
Contineum Therapeutics (CTNM) reported $0 in total revenue for fiscal year 2024. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Contineum Therapeutics's revenue growing?
Contineum Therapeutics (CTNM) revenue declined by 100% year-over-year, from $50.0M to $0 in fiscal year 2024.
Is Contineum Therapeutics profitable?
No, Contineum Therapeutics (CTNM) reported a net income of -$42.3M in fiscal year 2024.
What is Contineum Therapeutics's earnings per share (EPS)?
Contineum Therapeutics (CTNM) reported diluted earnings per share of $-2.18 for fiscal year 2024. This represents a -2825.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Contineum Therapeutics's EBITDA?
Contineum Therapeutics (CTNM) had EBITDA of -$50.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Contineum Therapeutics's free cash flow?
Contineum Therapeutics (CTNM) generated -$33.4M in free cash flow during fiscal year 2024. This represents a -276.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Contineum Therapeutics's operating cash flow?
Contineum Therapeutics (CTNM) generated -$32.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Contineum Therapeutics's total assets?
Contineum Therapeutics (CTNM) had $212.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Contineum Therapeutics's capital expenditures?
Contineum Therapeutics (CTNM) invested $514K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Contineum Therapeutics spend on research and development?
Contineum Therapeutics (CTNM) invested $38.4M in research and development during fiscal year 2024.
What is Contineum Therapeutics's current ratio?
Contineum Therapeutics (CTNM) had a current ratio of 20.69 as of fiscal year 2024, which is generally considered healthy.
What is Contineum Therapeutics's debt-to-equity ratio?
Contineum Therapeutics (CTNM) had a debt-to-equity ratio of 0.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Contineum Therapeutics's return on assets (ROA)?
Contineum Therapeutics (CTNM) had a return on assets of -19.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Contineum Therapeutics's cash runway?
Based on fiscal year 2024 data, Contineum Therapeutics (CTNM) had $21.9M in cash against an annual operating cash burn of $32.8M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Contineum Therapeutics's Piotroski F-Score?
Contineum Therapeutics (CTNM) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Contineum Therapeutics's earnings high quality?
Contineum Therapeutics (CTNM) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.